JPRN-UMIN000005366已完成2 期
A phase II study of trastuzumab added to docetaxel and S-1 for human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer. - A phase II study of trastuzumab added to docetaxel and S-1 for HER2-positive advanced gastric cancer.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) with severe allergy to Trastuzumab, S-1 and docetaxel 2) Active infection or other inflammatory disease 3) synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ 4) Other severe complications such as paralytic ileus, intestinal pneumonitis, pulmonary fibrosis, uncontrollable diabetes millutus, hypertension, and respiratory insufficiency. 5) History of cardiac disease 6) Dyspnea at rest, due to complications of advanced malignancy or other cardiovascular disease 7) Metastasis to CNS 8) Grade 3-4 peripheral sensory neuropathy 9) pregnant or nursing patient or with intent to bear baby 10) Inappropriate for the trial at the physician's assessment
研究者
相似试验
已完成
2 期
Phase 2 study of trastuzumab and docetaxel therapy for HER2-positive recurrent/metastatic salivary gland carcinomaHER2-positive salivary gland carcinomaJPRN-UMIN000018165Hokkaido University Hospital16
已完成
2 期
Second-line Trastuzumab/Docetaxel combination therapy in patients with HER2-positive metastatic breast cancer(MBC)- a phase 2 studyBreast cancerJPRN-C000000264H/D study group on Breast Cancer35
已完成
2 期
Phase II trial of trasutuzumab plus docetaxel for previous trastuzumab treated unresectable or recurrent HER2 positive gastric cancer (T-CORE1203)HER2 positive gastric cancerJPRN-UMIN000010869Tohoku Clinical Oncology, Research and Education Society(T-CORE)27
已完成
不适用
A phase II study of paclitaxel plus trastuzumab in patients with pretreated recurrent or metastatic gastric cancer.advanced gastric cancerJPRN-UMIN000006403Toyama Prefectural Central Hospital30
招募中
不适用
A phase II clinical study of trastuzumab in combination with capecitabine and cisplatin (XP) in patients with tissue HER2-negative but serum HER2-positive advanced gastric cancerNeoplasmsKCT0004391Asan Medical Center28